Andrew Abrams

Andrew Abrams joined New Science Ventures as an Associate in September 2016 and became a Partner in July 2020. He was formerly an Associate in J.P. Morgan’s healthcare investment banking practice in London, where he focused on mergers and acquisitions and debt and equity transactions in Europe and the U.S. He advised a wide array…

Read more

Raju Mohan

Raju Mohan joined New Science Ventures in 2017 as a Senior Advisor to the firm. He has over 25 years of drug discovery and development experience in pharma and biotech. Raju has co-founded multiple biotech companies, including Akarna Therapeutics (acquired by Allergan), Ralexar Therapeutics, Escalier Biosciences and Oppilan Pharma. Raju founded and served as President…

Read more

Jean-Pierre Bizet

Jean-Pierre Bizet joined New Science Ventures as a Partner and Senior Advisor in February 2015. Jean-Pierre is a non-executive director on several company boards, and a professor of strategy at Université Libre de Bruxelles. Previously, he was CEO of D’Ieteren, a listed diversified company in various distribution segments of the automobile sector. Until 2002, Jean-Pierre…

Read more

Tom Lavin

Tom Lavin is a co-founder and Partner of New Science Ventures. He serves on the Board of Directors for Achronix Semiconductor Corporation and Light Sciences Oncology and is an observer on the boards of Vorago, Juventas Therapeutics and Therox. He formerly served on the Board of Celleration (acquired by Aliqua). Prior to NSV, he was…

Read more

Somu Subramaniam

Somu Subramaniam is the co-founder and Managing Partner of New Science Ventures. Somu serves on the Board of Directors of Achronix Semiconductor Corporation, Ralexar Therapeutics, Cambridge Epigenetix, Dali Wireless, NorthSea Therapeutics, Oxyrane, Resolve Therapeutics, Svelte Medical Systems and Vascular Therapies. Somu has also served on the Boards of Dezima Pharma (acquired by Amgen), Ception Therapeutics…

Read more